Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
- Clinically Meaningful Improvements in Portal Hypertension in High Risk Compensated Cirrhosis Patients - - Conference Call and Webcast Presentation at 8:30 a.m. ET Today - SAN DIEGO, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq: …